Article Information
vol. 55 no. 6
PubMed
Published By
Print ISSN
Online ISSN
History
- Received March 25, 2020
- Accepted April 3, 2020
- Published online June 4, 2020.
Article Versions
- previous version (April 7, 2020 - 03:17).
- You are viewing the most recent version of this article.
Copyright & Usage
Copyright ©ERS 2020 This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
Author Information
- Maroun Khoury1,2,6⇑,
- Jimena Cuenca1,2,
- Fernanda F. Cruz3,4,
- Fernando E. Figueroa1,2,
- Patricia R.M. Rocco3,4 and
- Daniel J. Weiss5,6
- 1Laboratory of Nano-Regenerative Medicine, Faculty of Medicine, Universidad de los Andes, Santiago, Chile
- 2Cells for Cells and consorcio Regenero, Chilean Consortium for Regenerative Medicine, Santiago, Chile
- 3Laboratory of Pulmonary Investigation, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
- 4National Institute of Science and Technology for Regenerative Medicine, Rio de Janeiro, Brazil
- 5Dept of Medicine, University of Vermont, Burlington, VT, USA
- 6M. Khoury and D.J. Weiss contributed equally as lead authors of the study
- Maroun Khoury, Division of Nano-Regenerative Medicine, Faculty of Medicine, Universidad de los Andes, Av. La Plaza 2501, Las Condes, Chile. E-mail: mkhoury{at}uandes.cl
Funding
Comisión Nacional de Investigación Científica y Tecnológica
FONDEF 2016, IT16I10084
Article usage
Altmetrics
Vol 55 Issue 6
Table of Contents
Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19
Jump To
- Article
- Abstract
- Abstract
- Introduction
- Potential mechanisms of MSC actions in respiratory virus-induced lung injuries
- Effects of respiratory viruses on MSC actions
- Do MSCs express ACE2, the functional receptor of SARS-CoV-2?
- MSCs in respiratory virus-related lung injury: pre-clinical evidence
- Clinical investigations of MSC administration in patients with coronavirus or other respiratory virus-induced lung injury
- Assessment of the ongoing cell-based clinical trials registered during the COVID-19 outbreak
- Ethical issues for considering cell-based approaches for respiratory virus infections
- Challenges and perspectives
- Shareable PDF
- Acknowledgements
- Footnotes
- References
- Figures & Data
- Info & Metrics